• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder.伴有和不伴有预先存在的重度抑郁症的丙型肝炎患者的抗病毒完成率和持续病毒应答。
Psychosomatics. 2009 Sep-Oct;50(5):500-5. doi: 10.1176/appi.psy.50.5.500.
2
[Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients].[丙型肝炎病毒血清阳性（HCV）患者预防性精神科陪伴的益处：关于39例患者的前瞻性研究]
Encephale. 2003 Jul-Aug;29(4 Pt 1):362-5.
3
Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.精神疾病共病无法预测丙型肝炎血清学阳性退伍军人的干扰素治疗完成率。
J Clin Gastroenterol. 2007 Mar;41(3):322-8. doi: 10.1097/01.mcg.0000225629.22286.96.
4
Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.抗病毒治疗方案复杂性指数作为慢性丙型肝炎患者持续病毒学应答的独立预测指标
J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53. doi: 10.18553/jmcp.2013.19.6.448.
5
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.一项关于丙型肝炎患者中干扰素诱导的重度抑郁症发病率及开放标签治疗的前瞻性研究。
Mol Psychiatry. 2002;7(9):942-7. doi: 10.1038/sj.mp.4001119.
6
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.有精神疾病和/或物质使用障碍的丙型肝炎患者与无此类障碍患者的丙肝治疗模式比较。
J Viral Hepat. 2006 Apr;13(4):235-41. doi: 10.1111/j.1365-2893.2005.00681.x.
7
Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.直接作用抗病毒药物治疗丙型肝炎病毒合并精神障碍患者的真实世界疗效和安全性。
World J Gastroenterol. 2023 Jul 7;29(25):4085-4098. doi: 10.3748/wjg.v29.i25.4085.
8
Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review.慢性丙型肝炎退伍军人的抑郁症共病情况及抗抑郁药使用：一项回顾性病历审查结果
J Clin Psychiatry. 2008 May;69(5):810-6. doi: 10.4088/jcp.v69n0514.
9
[Reflections on the treatment of EDM in hepatitis C virus patients treated with interferon alpha from a retrospective survey concerning 29 patients].[一项关于29例丙型肝炎病毒患者接受α干扰素治疗时电火花加工处理的回顾性调查的思考]
Encephale. 2003 May-Jun;29(3 Pt 1):273-7.
10
HCV eradication in veterans with underlying mental health disorders and substance use.患有潜在精神健康障碍和物质使用问题的退伍军人的丙型肝炎病毒根除情况。
J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):1037-1043.e3. doi: 10.1016/j.japh.2020.08.028. Epub 2020 Sep 16.

引用本文的文献

1
Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study.丙型肝炎病毒感染治愈的注射吸毒者抑郁症状的减轻：HERO研究。
Open Forum Infect Dis. 2023 Oct 5;10(11):ofad498. doi: 10.1093/ofid/ofad498. eCollection 2023 Nov.
2
Declines in Depressive Symptoms Among People who Inject Drugs Treated With Direct-Acting Antivirals While on Opioid Agonist Therapy.接受阿片类激动剂治疗的同时使用直接作用抗病毒药物治疗的注射吸毒者抑郁症状的下降情况。
Open Forum Infect Dis. 2020 Oct 10;7(10):ofaa380. doi: 10.1093/ofid/ofaa380. eCollection 2020 Oct.
3
Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis.聚乙二醇化干扰素-α与利巴韦林联合治疗伊朗慢性丙型肝炎患者的精神科副作用：一项荟萃分析
Exp Ther Med. 2018 Aug;16(2):971-978. doi: 10.3892/etm.2018.6255. Epub 2018 Jun 6.
4
Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study.直接作用抗病毒治疗在无精神副作用的丙型肝炎真实世界患者中的应用：一项前瞻性观察研究。
BMC Psychiatry. 2018 May 29;18(1):157. doi: 10.1186/s12888-018-1735-6.
5
Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.基线抑郁的多方法评估及其与丙型肝炎治疗中断的关系。
Int J Psychiatry Med. 2018 Jul;53(4):256-272. doi: 10.1177/0091217417749796. Epub 2018 Jan 3.
6
Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.精神疾病与物质使用障碍共病及丙型肝炎：诊断与治疗意义
World J Hepatol. 2015 Jul 28;7(15):1921-35. doi: 10.4254/wjh.v7.i15.1921.
7
A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C.一项评估α干扰素疗法对慢性丙型肝炎成年患者认知和精神功能影响的纵向研究。
J Psychosom Res. 2015 Feb;78(2):184-92. doi: 10.1016/j.jpsychores.2014.07.020. Epub 2014 Aug 7.
8
Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.美国 HIV/HCV 共感染患者接受丙型肝炎抗病毒治疗的障碍：综述。
AIDS Patient Care STDS. 2014 May;28(5):228-39. doi: 10.1089/apc.2014.0033. Epub 2014 Apr 16.
9
Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.慢性丙型肝炎干扰素-α治疗中躯体症状性抑郁的易感性：一项 16 周前瞻性研究。
J Psychosom Res. 2013 Jan;74(1):57-63. doi: 10.1016/j.jpsychores.2012.10.012. Epub 2012 Nov 21.
10
Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.注射毒品者接受丙型肝炎治疗的障碍：误区与证据。
Hepat Mon. 2011 Jul;11(7):513-8.

本文引用的文献

1
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.有精神疾病和/或物质使用障碍的丙型肝炎患者与无此类障碍患者的丙肝治疗模式比较。
J Viral Hepat. 2006 Apr;13(4):235-41. doi: 10.1111/j.1365-2893.2005.00681.x.
2
Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders.
Psychiatr Serv. 2006 Mar;57(3):403-6. doi: 10.1176/appi.ps.57.3.403.
3
Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care.应对共病（丙型肝炎、精神障碍和物质使用）：常规心理健康筛查作为联合管理照护模式一部分的重要性。
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S286-91. doi: 10.1086/427442.
4
The phenomenology and treatment of interferon-induced depression.干扰素所致抑郁症的现象学与治疗
J Affect Disord. 2004 Oct 15;82(2):175-90. doi: 10.1016/j.jad.2004.04.002.
5
Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C.在对患有慢性丙型肝炎的退伍军人进行初次评估时，社会心理因素是抗病毒治疗最常见的禁忌症。
J Clin Gastroenterol. 2004 Jul;38(6):530-4. doi: 10.1097/01.mcg.0000123203.36471.70.
6
A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.一项关于慢性丙型肝炎患者接受α-2b干扰素和利巴韦林治疗相关神经精神症状的前瞻性研究。
Psychosomatics. 2003 Mar-Apr;44(2):104-12. doi: 10.1176/appi.psy.44.2.104.
7
National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.美国国立卫生研究院共识发展会议声明：丙型肝炎的管理：2002年——2002年6月10日至12日
Hepatology. 2002 Nov;36(5 Suppl 1):S3-20. doi: 10.1053/jhep.2002.37117.
8
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.一项关于丙型肝炎患者中干扰素诱导的重度抑郁症发病率及开放标签治疗的前瞻性研究。
Mol Psychiatry. 2002;7(9):942-7. doi: 10.1038/sj.mp.4001119.
9
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.坚持联合治疗可提高慢性丙型肝炎基因1型感染患者的持续应答率。
Gastroenterology. 2002 Oct;123(4):1061-9. doi: 10.1053/gast.2002.35950.
10
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎病毒感染
N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047.

伴有和不伴有预先存在的重度抑郁症的丙型肝炎患者的抗病毒完成率和持续病毒应答。

Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder.

机构信息

Northwest Hepatitis C Resource Center, Portland VA Medical Center, Portland, OR 97202, USA.

出版信息

Psychosomatics. 2009 Sep-Oct;50(5):500-5. doi: 10.1176/appi.psy.50.5.500.

DOI:10.1176/appi.psy.50.5.500
PMID:19855036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2987665/
Abstract

BACKGROUND

Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV.

OBJECTIVE

The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD).

METHOD

The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data.

RESULTS

The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups.

CONCLUSION

Patients with MDD can be safely and effectively treated with antiviral therapy.

摘要

背景

尽管有证据表明，大多数丙型肝炎病毒 (HCV) 患者都存在精神和物质使用障碍，但这些合并症患者在历史上一直被排除在 HCV 的抗病毒治疗之外。

目的

作者比较了患有和不患有先前存在的重度抑郁症 (MDD) 的丙型肝炎 (HCV) 患者之间的抗病毒药物完成率和持续病毒学应答 (SVR) 率。

方法

作者对参加 HCV 教育课程并签署知情同意书允许收集临床数据的 HCV 患者（30 例 MDD 和 25 例对照）进行了图表回顾。

结果

MDD 组的完成率和 SVR 率与对照组相似。两组之间的神经精神副作用和停药原因没有差异。

结论

MDD 患者可以安全有效地接受抗病毒治疗。